We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: clinical trial
MedXY News
EnglishTag

clinical trial

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Can Sertraline Reduce Repeat Violent Offenses? Insights from a Major Clinical Trial
newsclinical trialmental health

Can Sertraline Reduce Repeat Violent Offenses? Insights from a Major Clinical Trial

By MedXY|Dec 29, 2025

A large, rigorous study found that sertraline, an antidepressant, does not significantly lower the risk of repeated violent crimes among impulsive offenders.

Repurposing Hydroxychloroquine for Chronic Inflammatory Cardiomyopathy: Evidence from the HYPIC Multicenter Randomized Trial
Cardiologyclinical trialhydroxychloroquine

Repurposing Hydroxychloroquine for Chronic Inflammatory Cardiomyopathy: Evidence from the HYPIC Multicenter Randomized Trial

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
By MedXY|Dec 28, 2025

The HYPIC trial demonstrates that hydroxychloroquine combined with prednisolone significantly improves cardiovascular outcomes, cardiac function, and cytokine profiles in patients with chronic inflammatory cardiomyopathy following fulminant

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial
Cardiologyclinical trialfinerenone

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial

By MedXY|Dec 26, 2025

This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone’s efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity,

Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir
NeurologyAlzheimer's diseaseclinical trial

Antiviral Therapy Fails to Slow Alzheimer’s: The VALAD Trial Reveals Unexpected Cognitive Worsening with Valacyclovir

By MedXY|Dec 25, 2025

The VALAD randomized clinical trial found that valacyclovir did not improve outcomes in patients with early symptomatic Alzheimer’s and HSV seropositivity. Instead, patients receiving the antiviral showed significantly greater cognitive dec

Efficacy of mHealth Interventions for Smoking Cessation in Tuberculosis Patients: Insights from a Cluster Randomized Clinical Trial
AIclinical trialmHealth

Efficacy of mHealth Interventions for Smoking Cessation in Tuberculosis Patients: Insights from a Cluster Randomized Clinical Trial

By MedXY|Dec 24, 2025

An mHealth text messaging intervention significantly improves smoking cessation rates and reduces mortality among TB patients compared to usual care, supporting its implementation in TB programs.

Yoga vs Physical Conditioning: Evaluating Sleep Benefits in Women with Urinary Incontinence
newsclinical trialsleep quality

Yoga vs Physical Conditioning: Evaluating Sleep Benefits in Women with Urinary Incontinence

By MedXY|Dec 22, 2025

A secondary analysis of a randomized clinical trial finds that Hatha yoga does not provide superior sleep benefits compared to general physical conditioning in women with urinary incontinence, despite the strong correlation between nocturna

High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm
Infectious Diseasesclinical trialinfectious diseases

High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm

By MedXY|Dec 18, 2025

A multinational randomized trial found that adding high‑dose oral rifampin (total 35 mg/kg for 8 weeks) to standard therapy did not reduce 6‑month mortality in adults with tuberculous meningitis and was associated with more drug‑induced liv

Omega-3 Fatty Acids Show Limited Benefits for Diabetic Peripheral Neuropathy
Diabetes & Endocrinologyclinical trialdiabetes

Omega-3 Fatty Acids Show Limited Benefits for Diabetic Peripheral Neuropathy

By MedXY|Dec 17, 2025

Current evidence suggests minimal impact of omega-3 supplementation on neuropathy symptoms or quality of life in adults with diabetes.

Rethinking Oxygen Strategies for Preterm Infant Resuscitation: Evidence from TORPIDO, IPD-MA, and DCC Trials
Critical Careclinical trialoxygen therapy

Rethinking Oxygen Strategies for Preterm Infant Resuscitation: Evidence from TORPIDO, IPD-MA, and DCC Trials

By MedXY|Dec 16, 2025

Recent trials and meta-analyses challenge assumptions about optimal initial oxygen levels for preterm resuscitation.

Voucher for Healthy Foods and Diabetes Control: A Randomized Clinical Trial
Diabetes & Endocrinologyclinical trialdiabetes

Voucher for Healthy Foods and Diabetes Control: A Randomized Clinical Trial

By MedXY|Dec 13, 2025

This clinical trial evaluated monthly grocery vouchers for improving diabetes control in food-insecure patients, finding increased self-reported fruit and vegetable intake but no significant HbA1c improvement.

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial
Allergy & ImmunologyALSclinical trial

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial

By MedXY|Dec 6, 2025

The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark

Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)
Infectious Diseasesclinical trialtuberculosis

Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)

By MedXY|Nov 24, 2025

The Clo‑Fast phase 2c trial tested a 3‑month rifapentine‑clofazimine regimen versus standard 6‑month therapy for drug‑susceptible pulmonary TB. Culture conversion at 12 weeks was similar, but shorter therapy had higher grade ≥3 adverse even

Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development
Clinical Updatesclinical trialmalaria

Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development

By MedXY|Nov 23, 2025

This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advan

Laparoscopic Distal Gastrectomy Is Comparable to Open Surgery for Clinical T4a Gastric Cancer in Short-Term Outcomes: Results from the UMC‑UPPERGI‑01 RCT
General Surgeryclinical trialGastric Cancer

Laparoscopic Distal Gastrectomy Is Comparable to Open Surgery for Clinical T4a Gastric Cancer in Short-Term Outcomes: Results from the UMC‑UPPERGI‑01 RCT

By MedXY|Nov 14, 2025

The UMC‑UPPERGI‑01 randomized trial (n=208) found laparoscopic distal gastrectomy with D2 lymphadenectomy had similar 30‑day morbidity and mortality to open surgery for clinical T4a gastric cancer, despite longer operative times and modestl

Lazertinib Matches Osimertinib Efficacy in First-Line EGFR‑Mutant Advanced NSCLC: Exploratory Results from MARIPOSA
newsclinical trialeGFR

Lazertinib Matches Osimertinib Efficacy in First-Line EGFR‑Mutant Advanced NSCLC: Exploratory Results from MARIPOSA

By MedXY|Nov 12, 2025

In the MARIPOSA randomized, double-blind exploratory analysis, lazertinib monotherapy showed comparable progression-free survival, response rates, overall survival (interim), and tolerability to osimertinib in treatment-naive EGFR‑mutant ad

Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma
newsAntibody-drug conjugateclinical trial

Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma

By MedXY|Nov 11, 2025

A phase 3 randomized trial in China showed the EGFR/HER3 bispecific antibody‑drug conjugate izalontamab brengitecan produced a 54.6% objective response rate versus 27.0% with chemotherapy in heavily pretreated recurrent or metastatic nasoph

Durvalumab Combined with BCG for High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer: Final Phase 3 Trial Results from POTOMAC Study
newsBCGclinical trial

Durvalumab Combined with BCG for High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer: Final Phase 3 Trial Results from POTOMAC Study

By MedXY|Nov 11, 2025

One year of durvalumab combined with BCG induction and maintenance significantly improved disease-free survival in patients with high-risk, BCG-naive non-muscle-invasive bladder cancer compared to BCG therapy alone, with a manageable safety

Etrasimod Shows Robust Induction and Maintenance Efficacy in East Asian Patients with Moderate–Severe Ulcerative Colitis
Gastroenterologyclinical trialEtrasimod

Etrasimod Shows Robust Induction and Maintenance Efficacy in East Asian Patients with Moderate–Severe Ulcerative Colitis

By MedXY|Nov 9, 2025

A phase 3 randomized trial in East Asia found oral etrasimod 2 mg superior to placebo for induction and maintenance of clinical remission in moderate–severe ulcerative colitis, with manageable safety and notable ALT elevations.

Cilofexor Did Not Prevent Fibrosis Progression in Non‑Cirrhotic Primary Sclerosing Cholangitis: Results from the PRIMIS Phase 3 Trial
Gastroenterologyclinical trialprimary sclerosing cholangitis

Cilofexor Did Not Prevent Fibrosis Progression in Non‑Cirrhotic Primary Sclerosing Cholangitis: Results from the PRIMIS Phase 3 Trial

By MedXY|Nov 8, 2025

The phase 3 PRIMIS trial found cilofexor 100 mg once daily did not reduce histological fibrosis progression at 96 weeks in non‑cirrhotic primary sclerosing cholangitis; pruritus was more frequent with cilofexor.

Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial
Allergy & Immunologyatopic dermatitisclinical trial

Rilzabrutinib in Moderate-to-Severe Atopic Dermatitis: Assessing Efficacy and Safety in a Phase II Trial

By MedXY|Oct 28, 2025

A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.

Prev
4 / 10
123456…10
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities